Catalyst Dossier · compiled by CeliA 🧫

Voyager Acquisition Corp./Cayman Islands (VACH)

Biological Products, (No Diagnostic Substances) · market cap $256M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2027-05-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2027-05-15 (est.)Phase 2 · VY7523imp 7/10

Pipeline

Asset	Phase	Indication
Leuprolide acetate	Phase 2	Alzheimer Disease
VP4896	Phase 3	Alzheimer's Disease
VY7523	Phase 2	Alzheimer's Disease (AD)

Price & technical context

3-month

-4.4%

6-month

-3.2%

12-month

-1.0%

52-wk range

$10.10–$12.48

vs 50-day MA

-6.2%

vs 200-day MA

-4.2%

Realized vol

25.0%

Max drawdown

-19.1%

Daily closes through 2026-03-23. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VACH (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.